Compare DAO & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | TRVI |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2019 | 2019 |
| Metric | DAO | TRVI |
|---|---|---|
| Price | $12.08 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 89.3K | ★ 982.4K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.00 | $5.41 |
| 52 Week High | $13.04 | $16.12 |
| Indicator | DAO | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 45.75 |
| Support Level | $9.20 | $13.12 |
| Resistance Level | $13.01 | $14.57 |
| Average True Range (ATR) | 1.23 | 0.53 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 68.15 | 23.23 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.